Table 2.
Performance of the Urinary Galactofuranose-Antigen Detection Dipstick Assay
| IA Diagnosis | Subjects With Positive Tests, No. (%) | Sensitivity, % (95% CI) | Specificity, % (95% CI) |
|---|---|---|---|
| Overall cohort (n = 78)a | |||
| Proven/probable IA (n = 30) | 24 (80) | 80 (61.4–92.3) | 92 (74–99) |
| Controls (n = 25) | 2 (8) | ||
| Overall cohort, with β-d-glucan (n = 78)b | |||
| Proven/probable (n = 40) | 32 (80) | 80 (64.4–90.9) | 92 (74–99) |
| Controls (n = 25) | 2 (8) | ||
| Subgroup: hematological malignancy/BMT/neutropenia (n = 50)c | |||
| Proven/probable IA (n = 19) | 17 (89.5) | 89.5 (66.7–98.7) | 90.9 (58.7–99.8) |
| Controls (n = 11) | 1 (9.1) | ||
| Subgroup: noncancer (n = 28)c | |||
| Proven/probable IA (n = 11) | 7 (63.6) | 63.6 (30.8–89.1) | 92.9 (66.1–99.8) |
| Controls (n = 14) | 1 (7.1) | ||
Abbreviations: BMT, bone marrow transplant; CI, confidence interval; IA, invasive aspergillosis.
aExcludes 23 subjects with possible IA. Controls include no invasive fungal infection (IFI) or non-Aspergillus IFI.
bCase definitions considering β-d-glucan results, upgrading 10 subjects with possible IA to probable. Controls include no IFI or non-Aspergillus IFI.
cCancer subgroup excludes 20 subjects with possible IA and noncancer subgroup excludes 3 subjects with possible IA. Cancer subgroup includes 2 solid organ transplant recipients who had concurrent cancer with neutropenia.